Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Glucotrack (GCTK) Capital Expenditures (2016 - 2020)

Glucotrack's Capital Expenditures history spans 7 years, with the latest figure at $7000.0 for Q4 2020.

  • For the quarter ending Q4 2020, Capital Expenditures rose 1469.51% year-over-year to $7000.0, compared with a TTM value of $53000.0 through Dec 2020, up 130.43%, and an annual FY2025 reading of $96000.0, down 7.69% over the prior year.
  • Capital Expenditures for Q4 2020 was $7000.0 at Glucotrack, down from $31000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $31000.0 in Q3 2020, with the low at $446.0 in Q4 2019.
  • Average Capital Expenditures over 5 years is $10359.2, with a median of $6378.0 recorded in 2019.
  • Year-over-year, Capital Expenditures plummeted 93.83% in 2017 and then soared 1469.51% in 2020.
  • Tracing GCTK's Capital Expenditures over 5 years: stood at $28872.0 in 2016, then plummeted by 49.37% to $14618.0 in 2017, then plummeted by 87.23% to $1866.0 in 2018, then crashed by 76.1% to $446.0 in 2019, then soared by 1469.51% to $7000.0 in 2020.
  • Per Business Quant, the three most recent readings for GCTK's Capital Expenditures are $7000.0 (Q4 2020), $31000.0 (Q3 2020), and $15000.0 (Q1 2020).